-
21
The interplay between eosinophils and T cells in breast cancer immunotherapy
Published 2023-04-01“…Treatment with immune checkpoint inhibitors (ICI) has revolutionized cancer management for multiple tumor types, including breast cancer. …”
Get full text
Article -
22
Liquid biopsy biomarkers to guide immunotherapy in breast cancer
Published 2023-11-01“…Immune checkpoint inhibitors (ICIs) therapy has emerged as a promising treatment strategy for breast cancer (BC). …”
Get full text
Article -
23
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Published 2022-06-01“…Although breast cancer patients in general do not have a robust response to the immunotherapy, a subset of TNBC has been demonstrated to have high tumor mutation burden and high tumor-infiltrating lymphocytes, resembling the features observed on melanoma or lung cancers, which can benefit from the treatment of immune checkpoint inhibitors (ICIs). …”
Get full text
Article -
24
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Published 2021-11-01“…Immune checkpoint inhibitors (ICI) showed promising efficacy in triple-negative breast cancer (TNBC) treatment, namely Atezolizumab and Pembrolizumab. …”
Get full text
Article -
25
Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies
Published 2023-06-01Get full text
Article -
26
Meme kanseri tanısı ile göğüs duvarına radyoterapi uygulanan hastalarda iki farklı tekniğin karşılaştırılması
Published 2014-01-01Subjects: Get full text
Article -
27
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer
Published 2023-06-01“…Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent the mainstay of treatment for many tumor types, including triple-negative breast cancer and two agnostic registrations. …”
Get full text
Article -
28
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Published 2020-11-01“…With improved understanding of the immunogenicity of triple-negative breast cancer (TNBC), immunotherapy has emerged as a promising candidate to treat this lethal disease owing to the lack of specific targets and effective treatments. …”
Get full text
Article -
29
Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
Published 2023-03-01“…Though still incurable, metastatic breast cancer’s prognosis has been considerably improved in the past 10 years due to the introduction of new targeted agents, such as immune checkpoint inhibitors (ICI). …”
Get full text
Article -
30
Agonist Effects of Propranolol on Non-Tumor Human Breast Cells
Published 2020-04-01“…The β-blocker propranolol (PROP) has been proposed as a repurposed treatment for breast cancer. The similarity of action between β-agonists and antagonists found on breast cells encouraged us to compare PROP and isoproterenol (ISO, agonist) signaling pathways on a human breast cell line. …”
Get full text
Article -
31
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
Published 2020-05-01“…Triple negative breast cancer (TNBC) is an aggressive breast cancer with historically poor outcomes, primarily due to the lack of effective targeted therapies. …”
Get full text
Article -
32
Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy
Published 2021-05-01“…Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer that carries a particularly poor prognosis. …”
Get full text
Article -
33
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Published 2023-01-01“…The successful application of immune checkpoint inhibitors (ICIs) launched the era of immunotherapy in TNBC. …”
Get full text
Article -
34
Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions
Published 2023-09-01“…The rapid growth in ADC research has led to numerous developments and approvals for cancer treatment, with significant impacts on the management of breast cancer. ADCs like T-DXd for HER2-low disease and sacituzumab govitecan for triple negative breast cancer (TNBC) have provided valuable options for challenging subtypes of breast cancer. …”
Get full text
Article -
35
Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview
Published 2023-12-01“…Breast cancer (BCa) is known as a complex and prevalent disease requiring the development of novel anticancer therapeutic approaches. …”
Get full text
Article -
36
Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures
Published 2022-01-01“…Breast cancer is characterized by some types of heterogeneity, high aggressive behaviour, and low immunotherapeutic efficiency. …”
Get full text
Article -
37
-
38
Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
Published 2024-01-01“…Abstract Background Immune checkpoint inhibitors (ICIs) can improve survivals of metastatic triple negative breast cancer (mTNBC); however, we still seek circulating blood biomarkers to predict the efficacy of ICIs. …”
Get full text
Article -
39
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
Published 2023-01-01“…Immune checkpoint inhibitors (ICIs) deeply changed the treatment landscape of breast cancer (BC). …”
Get full text
Article -
40
Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy
Published 2024-01-01“…Emerging evidence suggests that only a subset of breast cancer patients benefit from ICI-based immunotherapy. …”
Get full text
Article